Affirm Holdings Inc. (AFRM) has been on a tear, delivering roughly 30% returns over the past year while analysts tout price targets suggesting another 30-40% upside. Retail enthusiasm is building, the stock was up about 3% by 10 AM Wednesday, and the BNPL darling looks unstoppable. But Kerrisdale Capital just threw a wrench into that narrative with a blistering short report titled "Buy Now, Cry Later."
The thesis? Affirm is running the same playbook that has torched subprime lenders for decades, and the downside risk is being dramatically underestimated.
Growth Built on Shaky Ground
Kerrisdale's central argument is straightforward: Affirm's explosive growth is masking serious credit deterioration. Sure, GMV has compounded at over 30% annually since 2022, but the short seller argues that expansion is fueled by increasingly aggressive lending to weaker and weaker borrowers.
Here's where it gets uncomfortable. Affirm's average loan yields now top 30%, with a meaningful chunk of revenue coming from high-APR products. Kerrisdale doesn't mince words—this isn't democratizing credit, it's extracting dollars from financially fragile consumers. And that strategy tends to work beautifully right up until it explodes.
Affirm did not immediately respond to a request for comment regarding the report.
Razor-Thin Cushions
The risk management picture makes things worse. Kerrisdale estimates Affirm is levered about six times, while loan loss reserves sit at a mere 1%-2% of GMV. That's a pretty slim buffer when normal loss rates in this business can run closer to 6%-7%.
If the labor market softens or delinquencies tick up, the math could unravel fast. Growth stalls, credit costs spike, and suddenly the path to sustained profitability vanishes.
A Valuation With No Room for Error
At current levels, Kerrisdale sees almost no cushion for disappointment. In a stress scenario, the firm argues Affirm could trade closer to book value—which would mean dramatic downside from today's price.
The timing adds another layer of tension. Earnings are scheduled for February 5, and political scrutiny of high-interest lending products is intensifying. Affirm is heading into what could be a make-or-break moment, and Kerrisdale is betting the market hasn't priced in the risk.
